Capacity of genetically different T lymphocytes to induce lethal graft- versus-host disease correlates with their capacity to generate suppression but not with their capacity to generate anti-F1 killer cells. A non-H-2 locus determines the inability to induce lethal graft- versus-host disease by unknown
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One of the  possible  consequences of the  graft-versus-host  reaction  (GVHR) 1 in 
animals and man is runt disease or acute graft-versus-host (GVH) disease (GVHD). 
It is frequently fatal and produces a variety of symptoms, which include atrophy of 
the  skin  and  the  gastrointestinal  mucosa and  hypoplasia of the  hemopoietic and 
lymphoid tissues manifested by anemia and immunodeficiency, respectively (1,  2). 
Donor T  cells are known to be responsible for the induction of runt disease (3, 4). 
However, the mechanisms by which T cells induce the pathological symptoms of runt 
disease are poorly understood. 
Another possible outcome of the GVHR is a  chronic GVHD which can lead to 
different conditions, such as lymphadenopathy (5, 6), immune complex glomerulo- 
nephritis (6,  7), and formation of multiple autoantibodies (8-11).  Previous analyses 
performed in nonirradiated Fa mice have shown that there are two minimal, essential 
requirements for the induction of the symptoms of chronic GVttD: immunocompetent 
T  lymphocytes must be present in the donor cell inoculum and they must be able to 
react to incompatible H-2 structures of the recipient (5-7, 9,  11). 
Undefined genetic factors of the T  cell-donor strain decide which of the two kinds 
of GVHD develop in the Fa hybrid recipients (5-7, 11). This point is best exemplified 
by previous studies on groups of identical (C57BL/6 ×  DBA/2)F1 or (C57BL/10 × 
DBA/2)F1 hybrid mice as recipients ofT cells from the donor strains DBA/2, C57BL/ 
6, C57BL//10, and B10.D2. When DBA/2 T cells were injected into these Fi hybrids, 
a  syndrome ensued that resembled systemic lupus erythematosus (7,  11). However, 
lymphadenopathy only rarely, and runt disease never, belonged to the spectrum of 
abnormalities induced by the donor DBA/2 (5, 11). 
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In contrast, when the other parental strains C57BL/6 and C57BL/10 were used as 
donors for groups of the same types of F1 recipients, a  different spectrum of GVHD 
developed.  This  involved  lymphadenopathy  and  lymphomas  (5,  6)  and  a  limited 
formation of autoantibodies (11), whereas severe immune complex glomerulonephritis 
never  developed  (7).  In  addition,  the  development  of  severe  runt  disease  as  an 
unwanted  side effect of GVHR  was  frequently observed (5,  11). As far as has been 
studied, a  syndrome similar to that  induced by C57BL/6  or C57BL/10  was evoked 
by  the  injection  of spleen  cells  from  strain  B10.D2  into  (C57BL/10  ×  DBA/2)F1 
recipients (5, 7,  11). 
These  genetic differences in  the  disease-inducing qualities of donor T  cells from 
strains C57BL/10  and B10.D2  versus strain DBA/2 deserve a  more detailed investi- 
gation. Therefore, we decided to study systematically the effects of GVHR,  induced 
by  either  strain  DBA/2  or  strains  on  a  B10-genetic  background,  upon  groups  of 
identical Fa hybrid recipients. 
Materials  and  Methods 
Mice.  C57BL/10ScSn mice and (C57BL/10 ×  DBA/2)F1 hybrids were purchased from the 
T.N.O.  Laboratory (Zeist, The Netherlands). B10.D2nSn  and  DBA/1  mice were purchased 
from The Jackson Laboratory (Bar Harbor, Maine). DBA/2 mice were purchased from GI. 
Bomholtg~rd  Ltd.  (Ry, Denmark).  Female B10.BR,  B10.S,  B10.G,  B10.M  and  B10.A mice 
were purchased from Olac Ltd. (Bicester, Oxfordshire, England). All F1 hybrid mice as well as 
[(B10.D2  X DBA/2)Fl ×  B10.D2] backcross mice were bred in our animal facilities, (Central 
Laboratory of The  Netherland  Blood Transfusion  Service, Amsterdam, The  Netherlands). 
Unless mentioned otherwise, female F1 hybrids, 8-10 wk old, were used as GVH recipients. 
Female DBA/2,  C57BL/10,  B10.D2,  B10.A, or backcross mice, 8-10  wk old, were  used  as 
donors. Female B10.BR and B10.G were first used to breed F1 hybrids with male DBA/2 and, 
at the age of 5-6 mo, they were used as GVH donors. 
Donor Cells for  Induction of GVHR.  Mice  were  killed and  their  spleens or  lymph  nodes 
(cervical,  axillary, inguinal,  and  mesenteric)  excised.  The  organs  were  minced  in  sterile, 
buffered-salt solution.  Single-cell suspensions  were  prepared  by  gently passing the  minced 
organs  through  a  nylon sieve and,  thereafter, through  Pasteur  pipettes filled with  1 cm of 
loosely packed sterile nylon wool. Bone marrow cells (BMC) were flushed with a needle and a 
syringe from  the  femoral  and  tibial cavities of donor  mice  and  collected in  sterile Hepes- 
buffered RPMI- 1640. 
Enrichment of Splenic T Cells.  To enrich for splenic T  cells, the method of Julius et al. (12) 
was used. Immunofluorescence studies showed that the cells not adhering to nylon wool usually 
contained  3-4%  B  cells, as determined by F(ab)2 rabbit  anti-mouse Ig serum  labeled with 
fluorescein isothiocyanate, and 60-80% T  cells, as determined by applying an appropriately 
absorbed rabbit anti-mouse brain serum in combination with swine anti-rabbit IgG labeled 
with fluorescein isothiocyanate (catalogue No. F 2190,  Dakopatts, Denmark). The viability of 
cells was determined by trypan blue exclusion; it was never <90%. 
Depletion of T  Cells.  For the depletion of T  cells, spleen-cell suspensions were prepared in 
Hepes-buffered RPMI-1640 that contained 5% fetal calf serum. 6-ml suspensions containing 30 
×  106 living cells/mi were incubated for 30 min at room temperature with monoclonal anti- 
Thy-1.2 serum (clone F7D5; Olac Ltd.) at a dilution of 1:1,000.  As a control, spleen cells from 
the same suspension were treated with normal mouse serum at a  dilution of 1:1,000.  Both 
suspensions were spun down and resuspended with 6  ml rabbit complement  (C) selected for 
low toxicity and diluted 1:30  in Hepes-buffered RPMI-1640. After incubation for 30 min at 
37°C, the cells were washed three times. The percentages ofT cells present in the anti-Thy-l.2- 
treated spleen-cell suspension from strain C57BL/10 was never >1%, whereas the spleen cells 
treated with normal mouse serum showed identical numbers of T  cells as the untreated spleen 
cells, i.e., 30% (range 27-35%). 
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spleen cells were injected i.v. into groups of irradiated (C57BL/10 ×  DBA/2)F1 hybrids, 10-14 
wk old. 1-3 h before injection, the F1 recipients were irradiated with 750 rad by using 662 keV 
gamma rays delivered by a X37Cs source. 5 d later, the spleens of these F1 animals were removed 
and pooled, and a single-cell suspension was prepared. Ceils were washed twice and cultured 
for 24 h in 5-ml amounts at a concentration of 5 ×  106 cells/ml. The culture medium consisted 
of sterile Hepes-buffered RPMI-1640 supplemented with L-glutamine (2 mM), 2-mercaptoeth- 
anol (2 ×  10  -s M),  10% fetal calf serum, streptomycin (50 U/ml), and penicillin (50 U/ml). 
Generation of Fl-activated Donor T Cells by Mixed Lymphocyte Reaction (MLR) In  Vitro.  Spleen 
cells were obtained under aseptic conditions, washed twice in sterile Hepes-buffered RPMI- 
1640 that contained 10% fetal calf serum and resuspended in culture medium. Normal spleen 
cells from (C57BL/10 ×  DBA/2)F1 hybrids were irradiated in vitro with 3,300 rad (667 rad/ 
min)  and served as stimulator cells. T  cell-enriched spleen cells were used as responder cells. 
Responder cells (12 ×  10  e) and stimulator cells (12 ×  106) were incubated in 5 ml medium for 
5 d at 370C in humidified air containing 5% CO2. 
Cell-mediated Lymphocytotox&ity (CML) Assay.  The CML activity of activated donor T  cells 
and the inhibition of CML activity with unlabeled target cells were determined and calculated 
as described elsewhere (13). 
Incorporation of SgFe and 5-['eal]lodo-Deoxyuridine (['esl]UdR)  into Lymphohemopoietic Organs. 
The  F1  mice received drinking water containing 0.1%  KI  during  24  h  before injection of 
isotopes. They were injected i.v. with a  mixture of 0.2 ~Ci [eaFe]citrate and 0.5/~Ci ~2~I-UdR 
(catalogue No.  IFS 2P,  1.M.355;  Amersham Corp., Arlington Heights, Ill.).  18  h  later, the 
spleens, thymuses, and one femur plus tibia were removed from the mice, and the 59Fe and x25I 
uptakes were measured in a gamma counter. The 125I uptake of the thymuses was corrected for 
the emission by 59Fe. 
IgG Production Assay.  This assay served to determine the amount  of IgG released into the 
culture supernate by cultured spleen cells from GVH  F1 mice.  Single-cell suspensions were 
prepared from the spleens of individual recipient mice in Hepes-buffered RPMI-1640. Eryth- 
rocytes were  lysed with  a  bicarbonate-buffered NH4C1  solution  (0.155  M  NH4C1,  0.01  M 
KHCO3, 0.1 mM EDTA; pH 7.4). After the cells had been washed in Hepes-buffered RPMI- 
1640,  1-ml aliquots containing 25 ×  106 live cells were cultured in RPMI-1640 that contained 
Hepes (10 mM), NaHCOn  (12 mM), glutamine (2 raM), fetal calf serum (10%), penicillin (50 
U/ml),  and  streptomycin  (50  U/mi).  The  cells were  cultured  for  18  h  at  37°C.  The  IgG 
concentrations in the culture supernates were determined by a solid-phase radioimmunoassay 
specific for mouse IgG. 
Radioimmunoassay for the Quantitation of Mouse IgG in Supernates of Cultured Spleen Cells.  The 
principle of the assay was a slight modification of the solid-phase double-sandwich technique 
described by Habermann (14). The solid-phase consisted of rabbit anti-mouse IgG coupled to 
Sepharose  4B  (Pharmacia  Fine  Chemicals,  Uppsala,  Sweden).  Mouse  IgG  from  the  test 
specimen after having reacted with this was detected by the use of 125I-labeled anti-mouse IgG. 
The same rabbit anti-mouse antiserum was used for the solid-phase and 12hi-labeling;  it was 
prepared by immunization of rabbits with the Fc fragments of polyclonal mouse IgG. Applying 
pure myeloma mouse IgG (catalogue No. 8402-24, Bionetics, Kensington, England) to obtain 
a reference curve, the IgG concentration in the test samples could be determined by comparison. 
IgG concentrations of 100-3,000 ng/ml could be quantitated. The test failed to detect myeloma 
IgM (TEPC  183; catalogue No. 8402-39, Bionetics) at a concentration of up to 10,000 ng/ml. 
Results 
Ability of BlO Strains and Inability of DBA Strains to Induce Lethal Runt  Disease (Table 
I).  For the induction of lethal runt  disease, groups of nonirradiated F1 mice were 
injected i.v. with 60 ×  106 donor spleen or lymph node cells. Whereas the vast majority 
of female  (C57BL/10  X  DBA/2)Fa  mice  injected  with  spleen  or  lymph  node  cells 
from B 10.D2 and C57BL/10 mice, respectively, died from runt disease, those F1 mice 
injected with spleen or lymph node cells from DBA/2 survived and did not show even 
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TAnLE  I 
Comparative Survival of Ft Recipients Injected i.v. with 60 ×  106 Lymphoid Cells of Different Origin 
Donor strain  Fl hybrid recipients 
Survivors at week indicated 
Spleen  Lymph  BMC  Strain  H-2 incom-  Num- 
cells  node cells  patibility  her 
2  4  6  8  10  12  14 
BI0.D2 
DBA/2 
DBA/2 
C57BL/10 
BI0.D2 
BI0.D2 
DBA/2 
BI0,D2 
DBA/2 
B lO.D2 
BIOBR 
BI0.A 
DBA/2 
BI0.D2 
BIO.G 
DBA/I 
DBA/2 
BI0.D2 
BI0.D2 
% 
(BI0.D2 X  DBA/2)FI  None  12  100  100  100  100  100  100  100 
(C57BL/10 x  DBA/2)Ft  H-2  h  20  100  100  100  I00  100  1130  I00 
(C57BL/10 x  DBA/2)Fa  H-2  b  12  100  100  lif0  100  100  100  100 
(C57BL/10 x  DBA/2)F~  H-2  a  29  100  66  28  24  21  10  3 
(C57BL/10 X  DBA/2)FI  H-2  ~  20  100  60  40  20  15  15  5 
(C57BL/10 x  DBA/2)F~  H-2  b  33  100  18  12  12  12  12  12 
(C57BL/10 X  DBA/2)F~  H-2  h  10  i00  100  100  100  100  100  100 
(B10.M X  DBA/2)F~  H-2  f  16  100  100  100  100  100  100  100 
(BI0.M x  DBA/2)F~  H-2  t  29  100  30  17  14  14  14  14 
(BI0.BR X  DBA/2)F~  H-2  k  16  100  100  100  100  100  100  100 
(BI0.BR X  DBA/2)F:  H-2  k  19  t00  44  16  11  11  0  0 
(B10.BR X  DBA/2)F,  H-2  n  20  |00  89  68  47  36  31  31 
(BI0.BR X  DBA/2)Fx  H-2  I'/a*  39  100  30  3  3  3  3  3 
(BI0.G X  DBA/2)FI  H-2  q  15  100  I00  100  100  ]00  ]00  100 
(B 10.G X  DBA/2)FI  H-2  q  11  100  64  18  18  18  9  9 
(B I0.G X  DBA/2)Ft  H-2  n  17  I00  0  0  0  0  0  0 
(B10.G ×  DBA/2)F1  H-2  a  15  100  100  100  100  100  100  100 
(BI0.S ×  DBA/2)F~  H-2  ~  18  100  100  100  100  100  100  100 
(B10.S ×  DBA/2)F~  H-2"  13  100  92  85  85  85  77  77 
* The H-2 incompatibility  between BI0.A and (BI0.13R ×  DBA/2)FI consists of the d  haplotype at the left-hand side (K through I-E) and of 
the k haplotype on the right-hand side  (I-C through D). 
with  that of spleen  or lymph  node cells,  failed  to induce lethal runt disease.  When 
male  (C57BL/10  X  DBA/2)F1  hybrids were  used  as  recipients  of spleen  cells  from 
either male  C57BL/10  or male  DBA/2  donors, we  again observed  that most  of the 
C57BL/10-cell-injected,  but none of the DBA/2-cell-injected,  F1 recipients died from 
lethal runt disease (data not shown). 
The antigens that elicited the lethal reaction of donor T  cells were determined by 
the H-2 complex  of the F1 recipients.  This  is evident  from  the complete  absence of 
GVH mortality in (B10.D2 ×  DBA/2)F] recipients (H-2 d/a) injected with B10.D2  (H- 
2  old)  spleen  cells.  The  only difference  between  these  F1  hybrids  and  (C57BL/10  × 
DBA/2)F1  hybrids (H-2 b/a) resides in the H-2 complex. 
In the presence of an H-2 incompatibility in the F1 recipient strains and irrespective 
of the H-2 incompatibilities involved, the injection of B 10.D2 spleen cells consistently 
induced lethal  runt disease.  All  the other H-2-congenic-resistant  donor strains on a 
B10  background,  namely  B10.BR,  B10.A,  and  B10.G,  likewise  induced  lethal  runt 
disease when injected into the corresponding H-2-incompatible F~ hybrids. If an H°2 
incompatibility  existed  between  the  recipients  and  donor  spleen  cells  that  were 
administered,  the only mice that did not develop lethal runt disease were those that 
received DBA/2 or DBA/1  cells. 
Although the GVH  reactivity of the five H-2-congenic resistant  B10 donor strains 
was  fairly uniform in that all of them were capable  of indficing lethal runt disease, 
there were differences  in the extent to which this occurred  (Table I).  Possibly, these 
quantitative  differences  are caused by the different  H-2 alleles of the donor and F~ 
strains involved. 
A Recessive Non-H-2 Locus Codes for the Capacity of BlO.D2 to Induce Lethal Runt Disease 
(Table II).  (C57BL/10  ×  DBA/2)F1  hybrids were injected i.v. with 60 ×  106 donor 1478  GENETICS OF T  CELL SUPPRESSION IN GRAFT-VS.-HOST DISEASE 
TABLE II 
Comparison of Individual Donor Mice of Different Origins with Respect to 
Their Capacity to Induce Lethal Runt Disease in (C57BL/ lO × 
D  BA / 2  ) FI Hybrids 
Donor mice (H-2 d/d) 
FI hybrid recipients (H-2b/a)  * 
Number 
tested 
Survivors at week indi- 
cated 
4  8  14 
% 
(B10.D2 X DBA/2)F1  17  100  100  100 
B10.D2  17  70  30  11 
Backcrosses  47  93  68  47 
* Each F1 hybrid recipient received an i.v. injection of 60 x  106 live spleen 
cells obtained from  an individual donor mouse, 
spleen cells of individual  donors.  The following kinds of donor were used:  (B10.D2 
×  DBA/2)F1,  [(B10.D2  ×  DBA/2)F1  ×  B10.D2]  backcross, and B10.D2 mice. None 
of the recipients of (B 10.D2 ×  DBA/2)F1 spleen cells died from runt disease, indicating 
that  the  runt  disease-inducing  capacity of B10.D2  is  recessive to  the  noninducing 
capacity of DBA/2. As expected, most (89%)  of the recipients of B10.D2 spleen cells 
died from runt disease. When spleen ceils from 47 individual  [(BIO.D2 ×  DBA/2)F1 
×  B10.D2]  backcross mice were used as donor-ceU inocula,  53% of the F1 recipients 
died  from runt  disease.  Statistical  analysis of the numbers of F1  hybrids  that  were 
dead at  14 wk after the induction of GVHR was performed by applying the binomial 
test.  We examined  the probabilities  that  the  percentage of runted  F1  recipients of 
spleen cells from individual  backcross donors were 50 and  25%, respectively, of the 
percentage of runted F1 recipients of spleen cells from individual B 10.D2 donors. The 
hypothesis that this value is 50% was not rejected (P -- 0.27), whereas the hypothesis 
that it is 25% was clearly rejected  (P =  0.001).  These observations indicate that the 
difference in the runt disease-inducing capacity between strains B10.D2 and DBA/2 
is determined by one genetic locus, or a number of closely linked loci. 
Capacity of B l O Donor Strains to lnduce Lethal GVHD Is Associated with Their Capacity to 
lnduce Aplastic Anemia and Thymic Hypoplasia  (Tables 11land IV).  Injections of 60 ×  106 
spleen  cells  from  C57BL/10  or  B10.D2  into  (C57BL/10  ×  DBA/2)F1  recipients 
strongly suppressed the 59Fe incorporation into bone marrow of the recipients, whereas 
the injection of DBA/2 spleen cells did not. In contrast, the incorporation of 59Fe into 
the spleen was increased, especially if C57BL/10 or B10.D2 spleen cells were injected 
(Table III). Nevertheless, the net effect of the injection of spleen cells from C57BL/10 
or B10.D2  on hemopoiesis was a  severe decrease of the hematocrit  values of the F~ 
recipients.  Such  a  decrease was not observed after the injection  of spleen cells from 
DBA/2. 
The strongly suppressive effects upon  hemopoiesis in  the bone marrow of the F1 
recipients were not observed when 60 ×  106 B 10.D2 BMC instead of spleen cells were 
administered. This suggests that mature donor T  cells were required for the induction 
of hemopoiesis suppression. When 60 ×  106 B 10.D2 (H-2  d/d) spleen cells were injected 
into  (B10.D2  ×  DBA/2)FI  hybrids  (H-2d/d),  the  suppression  of hemopoiesis  in  the VAN ELVEN, ROLINK, VAN DER VEEN, AND GLEICHMANN  1479 
TASLE III 
Comparison of the Effect of Spleen Cells and BMC  from Different Donor Strains upon the Hemopoiesis ofF1 
Hybrid Recipients 
Fl hybrid recipients* 
~aFe incorporation into 
Exp.  Donor cells  H-2 incom- 
Strain  Bone marrow  Spleen 
patibility 
Week 3  Week 4  Week 3  Week 4 
nematocrit values 
Week 3  Week 4 
Spleen cells 
(C57BL/10  × 
DBA/2)F~  (C57BL/10 ×  DBA/2)F~  None  100 ±  6:~  100 ±  4  100 ±  14  100 ±  I 1  41.5 ±  0.3  46.6 ±  0.5 
DBA/2  (C57BL/10 ×  DBA/2)Ft  H-2  b  80 ±  9~  89 ±  61[  127 ±  1611  182 ±  21¶  45.5 ±  0.7¶  42.4 ±  0.7¶ 
C57BL/10  (C57BL/10 x  DBA/2)F~  H-2  d  23 ±  2¶  38 ±  9~  240 ±  27¶  233 :t= 31¶  27.0 ±  0.4¶  37.6 :t: 1.4¶ 
BI0.D2  (C57BL/10 ×  DBA/2)Ft  H-2  b  36 ±  6¶  42 ±  4¶  225 ±  12¶  276 -4- 28¶  27.5 ±  2.3¶  36.3 ±  0.8¶ 
Spleen cells 
(BI0.D2  X 
DBA/2)FI  (BI0.D2 X DBA/2)F1  None  100 ±  9  100 =t: 7  100 ±  13  104) ±  23  45.4 ±  0.5  44.4 ±  0.5 
B10.D2  (B10.D2 X  DBA/2)F1  None  92:1:61  69 ± lOll  99 ± 1611 201 ± 31§  45.7  +  0.611  43.2  ± 1.611 
BMC 
(C57BL/10  x 
DBA/2)Fa  (C57BL/IO ×  DBA/2)F~  None  1013 +  8  100 :i: 4  100 ±  17  100 ±  17  47.2 +  0.5  47.8 ±  0.2 
B10.D2  (C57BL/10 ×  DBA/2)Ft  H-2  b  93 ±  10~  I  79 ±  8§  83 ±  2411  122 ±  511  47.6 ±  0.7[]  47.2 ±  0.411 
* Groups of mice were injected with 60 X  10  e cells of the indicated donor strain: experiment  1 consisted of groups of 9-11 mice; experiments 2 and 3 
consisted of groups of 4-6 mice. 
¢ Mean ±  SE expressed as percentage of the values found in syngeneically injected F1 hybrids. Statistical analyses were performed by Student's t test. 
§ 0.Ol <  P <  0.05 when compared with the values found in syngeneically injected Fi hybrids. 
II v > 0.05. 
¶ P<  0.01. 
bone marrow was much less severe than  after injection  of these cells into  the H-2- 
incompatible (C57BL/10 ×  DBA/2)FI hybrids (H-2  b/d) (Table III). Because the two 
kinds of Fx recipient were identical except for their H-2 alleles, we can conclude that 
an H-2 difference between donor and host was required for a profound depression of 
hemopoiesis. 
Thymic hypoplasia  was  quantitated  by the  incorporation  of [I2SI]UdR  into  the 
thymuses of (C57BL/10  ×  DBA/2)F1  recipients.  Injection of 60  ×  106 spleen  cells 
from both C57BL/10  and  B10.D2  led  to a  severe suppression  of thymic  [125I]UdR 
incorporation  at both weeks 3 and 4  (Table IV). By contrast,  injection of 60  ×  l06 
DBA/2 spleen cells failed to induce a  significant suppression at week 3 and even led 
to a  moderate stimulation of thymic cell proliferation at week 4  (Table IV). 
Thymic hypoplasia was not observed when 60 ×  l06 B 10.D2 BMC instead of spleen 
cells were  injected  into  (C57BL/10  ×  DBA/2)Fa  hybrids,  suggesting that  donor T 
cells were needed to induce thymic hypoplasia. When 60  ×  106 B10.D2 spleen cells 
were injected  into  (B10.D2  X  DBA/2)F1  hybrids,  no significant  decrease of thymic 
cell proliferation was observed (Table IV), indicating that an H-2 difference between 
donor cells and recipients is necessary for the induction of thymic hypoplasia. 
Capacity of Donor Strains to Induce Lethal GVHD Is Associated with the Capacity to Suppress 
Splenic IgG Production in the F1 Hybrid Recipients (Table  V).  Several Fa hybrid strains 
were  prepared  by mating various  H-2-congenic  resistant  El0  strains  with  DBA/2. 
Mice of these F1 strains were injected with spleen cells from either DBA/2 or a  B10 
strain (Table V). After 14 d, the spleen cells of the F1 recipients were assayed in vitro 1480  GENETICS  OF  T  CELL  SUPPRESSION  IN  GRAFT-VS.-HOST  DISEASE 
TABLe  IV 
Comparison of the Effect of Spleen Cells and BMC Obtained  from  Various Donor Strains upon the Thymic 
Uptake of [ tZ~l] UdR of G VH FI Recipients 
Exp.  Donor cells 
Ft hybrid recipients* 
Strain 
H-2 in-  llzSI]UdR uptake ofthy- 
com-  muses 
patibil- 
ity  Week 3  Week 4 
Spleen ceils 
(C57BL/10  X  DBA/2)F~  (C57BL/10  x  DBA/2)F~  None  100 +  10:[:  100 +  9 
DBA/2  (C57BL/10  X  DBA/2)F~  H-2 b  83 ±  13§  124 +  14§ 
C57BL/10  (C57BL/10  X  DBA/2)F~  H-2 d  18 +  411  28 ±  511 
B10.D2  (C57BL/10  x  DBA/2)Ft  H-2 b  9  ±  o.311  23 ±  411 
Spleen cells 
(B10.D2  X  DBA/2)F~  (B10.D2 X  DBA/2)F~  None  100 +  9  100 +  13 
B10.D2  (BI0.D2 X  DBA/2)Fa  None  95 +  6§  88 ±  11§ 
BMC 
(C57BL/10  x  DBA/2)F~  (C57BL/10  ×  DBA/2)FI  None  100:1:19  100 ~  11 
B10.D2  (C57BL/10  X  DBA/2)F~  H-2 '~  77 +  13§  96 +  20§ 
* Same GVH mice as in Table III. 
:l: Mean  ±  SE expressed as percentage of the values found  in syngeneically injected  F~ hybrids.  Statistical 
analysis was performed  by Student's t test. 
§ P >  0.05 when compared with the values found in syngeneically injected F1 hybrids. 
II P  <  0.0t. 
TABLE  V 
Comparison of the Effect of Spleen Cells Obtained  from  Various Donor Strains upon the Production of lgG 
by Cultured Spleen Cells of GVH Ft Recipients 
Ft hybrid recipients* 
Donor strain 
for induction 
of GVHR  Strain 
H-2 in- 
compati- 
bility 
]g'G in supernates of cultured spleen cells obtained from Fl mice injected with 
the stated number (×  l0  n) of donor spleen cells 
0  10  30  100  3OO 
(C57BL/10  × 
DBA/2)F,  (C57BL/10 ×  DBA/2)F~  None  IOO 3= 21:[:  NT§  97 3=  1711  97 ±  241l  107 + 511 
C57BL/10  (C57BI./10 ×  DBA/2)FI  H-2  a  IOO 3= 24  193 +  39¶  292 3= 63**  30 ±  9**  24 3= 2¶ 
DBA/2  (C57BI,/10 ×  DBA/2)F~  H-2  t'  100 ..i- 29  341  ±  126¶  511  ±  104"*  5,003 +  1,083"*  7,530 ±  885** 
B 10.D2  (C57BL/10 ×  DBA/2)F~  H-2  h  1OO 3= 22  45 ±  I 1¶  28 +  8**  122 ±  3611  46 3= 8¶ 
BIO.BR  (B IO.B"R ×  DBA/2)F~  H-2  a  100 ±  13  128 3= 3111  81  3=  1911  20 3= 3**  NT§ 
DP, A/2  (BI0.BR ×  I)I~A/2)F~  H-2  k  100 3= 36  313 3= 76¶  553 3= 96**  188 +  3511  1,175 ±  359** 
DBA/2  (BI0.S.×  DB,A/2)Fa  H-2"  100 3= 21  223 ±  36¶  689 ~  146"*  102 ±  1711  1,965 3= 289** 
DBA/2  (BI0.G ×  DBA/2)F~  H-2  '~  IOO 3=  18  139 ±  2511  255 ±  63¶  807 3= 261"*  761 3= 42411 
I)BA/2  (BI0.M ×  IJBA/2)F~  H-2  +  tOO 3= 22  148 +  2411  605 +  145"*  21 ~ 3= 7211  3,511 3= 993** 
* Groups of five F+ recipient mice were injected eithe~  i,v. with  10, 30, and  IOO X  l0  s donor spleen cells ur Lp. with 300 ×  10  n donor spleen cells 
per recipient. After  14 d, 25 ×  l0  s recipient spleen cells were cultured and the lgG concentration  in the culture supernatcs  was determined. 
~: Expressed as a  percentage of the IgG concent ration found in the culture supernates ~f spleen t:elts from n(mir\iect"ed  syngeneic Ft mice (n:ear~ 
±  SE). Statistical analysis was performed by Student t test. 
§ Not tested. 
11P >  0.05 when compared with the values found in noninjected syngeneic Fl nticc. 
¶ 0.01 <.  P <  0.05. 
** P<  0,01. VAN  ELVEN,  ROLINK,  VAN DER  VEEN, AND GLEICHMANN  1481 
for the amount of IgG released. Although spleen cells of the donor DBA/2 consistently 
failed to suppress and, in  most instances,  induced  a  marked stimulation of the IgG 
production  of the  spleen  cells  of the  recipients,  the  B10  donor  strains  induced  a 
marked suppression of the IgG production that was most profound after the injection 
of  high  doses  of  donor  spleen  cells.  The  induction  of  markedly  increased  IgG 
production  after  the  injection  of  DBA/2  cells  depended  on  the  presence  of  T 
lymphocytes in the donor inoculum and on an H-2 incompatibility in the FI hybrid 
recipients (E. H. van Elven, unpublished results). 
The  suppression  of IgG production  in  the  spleen  cells  of the  recipients  likewise 
depended  on the injection of donor T  cells.  Although C57BL/10  donor spleen cells 
that had been treated with normal mouse serum and C induced a marked suppression 
of IgG production  in the F1 recipients, the same number of those C57BL/10  spleen 
cells that remained alive after treatment with anti-Thy-l.2 and C did not (Table VI). 
Inability  of Strain DBA/2 to Induce Lethal Runt Disease is Not a Result  of an Inability  to 
Generate Anti-Fx Killer T  (T  K) cells.  T  cell-enriched spleen cells of the donor strains 
C57BL/10,  B10.D2,  and  DBA/2  were  activated  against  Fx  antigens  in  750-rad- 
irradiated (C57BL/10 ×  DBA/2)F1 hybrids, cultured for 1 d, and subsequently tested 
by  CML  on  F1  target  cells.  Fig.  1 shows  that  virtually  no  difference  in  cytotoxic 
activity could be detected  among the three strains.  Similarly, when T  cell-enriched 
spleen cells of the same donor strains were first activated against F1 by MLR (applying 
a responder:stimulator cell ratio of 1:1)  and then assayed by CML on F1 target cells, 
hardly  any difference  in  cytotoxic anti-Fx  activity could  be detected  (Fig.  2).  The 
cytotoxic cells generated in this way were completely destroyed by treatment of the 
activated cells with anti-Thy-1.2 and complement; in one experiment, a reduction of 
the specific lysis from 30 to 2% was observed. Cold-target inhibition experiments with 
both  in  vivo and  in  vitro activated donor spleen  cells indicated  that  the cytotoxic 
activity of T K cells  from  DBA/2  and  B10.D2  was specifically directed  against  the 
opposite H-2 of the F1 target cells (Table VII). 
Discussion 
Although  differences in the GVHR-inducing capacities of different inbred mouse 
strains have previously been reported (5, 7, 15, 16), the present data represent the first 
TAaLE VI 
T Lymphocytes of the C57BL/10 Donor Are Required  for the Suppression of 
Splenic lgG Production in FI Hybrid Recipients 
Splenic IgG 
C57BL/10 donor spleen cells*  production in 
F1 recipients~ 
None  100 ± 8 
100 X 106 treated with normal mouse serum and C  14 5: 3§ 
I00 ×  10  n treated with anti-Thy-l.2 and C  240 ± 72§ 
* Donor spleen cells were first treated as indicated and then the stated number 
of live cells was injected. 
:[: Grou~as of five (C57BL/10 x  DBA/2)FI hybrids were injected i.v. with 100 
x  10  live  cells. After 14 d the F1 spleen cells splenic IgG production was 
determined. The results are expressed and statistically analyzed as described 
in the legend of Table IV. 
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FIG.  1.  Comparison of the anti-Fl cytotoxic activity of T  cells from strains C57BL/10,  DBA/2, 
and B 10.D2. T  cell-enriched spleen cells from the respective donor strains were activated for 5 d  in 
the spleens of irradiated  (C57BL/10 ×  DBA/2)F1 hybrids. Thereafter, they were assayed by CML 
by using SlCr-labeled concanavalin A blast cells from syngeneic F1 mice as target cells. 
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FIG.  2.  Comparison of the anti-F]  cytotoxic activity of T  cells from strains C57BL/10, DBA/2, 
and BI0.D2. T  cell-enriched spleen cells from the donor strains were activated for 5 d  in an MLR 
by irradiated spleen cells from (C57BL/10 X DBA/2)Fx. Thereafter, they were assayed by CML on 
~]Cr-labeled concanavalin A blast cells from syngeneic F] mice. 
systematic  multiparameter  analysis  of such  differences.  Our  experiments  were  de- 
signed in such a  way that  lymphocytes obtained from several donor strains, strains 
DBA/2 and B 10.D2 in particular, could be compared as donor cells for the induction 
of GVHR in groups of identical F1 hybrid recipients. In contrast with the T  cells of 
the B 10 donor strains, those of strain DBA/2 consistently failed to induce lethal runt 
disease (Table I) or the symptoms associated with it (Tables III and IV). In previous 
studies,  it  has  been  observed that  even  doses  much  higher  than  60  ×  l0  s  DBA/2 
spleen and/or lymph node cells, likewise failed to induce lethal runt disease, but led 
to a chronic form of GVHD, whose hallmark was immune complex glomerulonephritis 
(5-7). However, it should be noticed that, as far as the induction of lethal GVHD by 
spleen cells from the B10 strains is concerned, the absolute number of cells required 
can  vary  (data  not  shown).  In  our  experience,  this  variability was  a  result  of the VAN ELVEN,  ROLINK, VAN DER  VEEN,  AND GLEICHMANN 
TABLE VII 
Cold-Target Cell Inhibition of Genetically Different T K Cells Activated 
Against Antigens of (C57BL/ IO ×  DBA/2)Ft Hybrids 
Effector ceils*  Cold-target inhibition:~ 
with cells from 
Mode of acti-  (B10.D2 ×  C57BL/10 
DBA/2) F1  (H.2b/b)  Strain  vation  (H_2d/d) 
C57BL/10  (H-2  u/b)  In vivo  97 ±  1  5 + 2 
In vitro  96 ± 2  1 ±  1 
DBA/2 (H-2  d/d)  In vivo  8 ± 2  98 ±  1 
In vitro  3 ±  1  92 + 3 
B10.D2 (H-'2  'i/d)  In vivo  10 ± 2  98 ±  1 
In vitro  2 ±  1  86 ± 3 
* The  activated effector  cells were  tested  by CML  with  concanavalin  A- 
stimulated, SlCr-labeled (C57BL/10 × DBA/2)F1 spleen cells as target cells, 
at an effeetor:target  cell ratio 12.5:1. During CML, unlabeled (cold) target 
cells, either (B10.D2 ×  DBA/2)F1 or C57BL/10 concanavalin  A-stimulated 
spleen cells, were added at an unlabeled:labeled target cell ratio of 20:1. 
:~ Inhibition +  SD was calculated as percentage of specific lysis obtained in 
control cultures to which no unlabeled target cells were added. 
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hygienic quality of the environment  in which  the animals were housed.  This obser- 
vation is consistent with the demonstration that the quality of the intestinal microflora 
exerts a  tremendous influence on the mortality rate of mice undergoing GVHR  (17). 
A  rather poor capability of strain  DBA/2  to induce  lethal GVHD  has  also been 
described  in  studies  with  parabiotic  mice  where  a  better  survival  was  found  in 
parabionts made between strains DBA/2 and, for instance, (DBA/2 ×  CBA)Fx than 
in  parabionts  made  between  BALB/c  and  (BALB/c  ×  CBA)F1  (15,  18).  However, 
this experimental design did not allow a  comparison of the different parental strains 
in  groups  of  genetically  identical  Fa  hybrids.  Therefore,  the  possibility that  the 
different survival rates observed with the various parental strains were also influenced 
by the different kinds of Ft hybrids could not be excluded. 
T  lymphocytes of the donor are required for the induction of lethal runt disease by 
the GVHR  (3, 4).  In the present investigation, this was reflected by the finding that 
inocula  of B10.D2  spleen  or  lymph-node  ceils killed the  (C57BL/10  ×  DBA/2)Fx 
recipients, whereas  BMC  completely failed to  do  so  (Table  I).  Mouse  spleens  and 
lymph  nodes  contain  30-35  and  65-79%  of T  cells,  respectively  (19),  but  BMC 
comprise only ~2-7% of mature T  cells (20). 
The  ability of strain B10.D2  and  inability of strain DBA/2  to induce lethal runt 
disease was observed in all the H-2-incompatible F1 strains tested (Table I). Although 
these two donor strains are H-2-identical and their T  cells thus recognized the same 
H-2 incompatibilities in all recipients, only strain DBA/2 failed to kill the F1 hybrids. 
Hence, both the ability of strain B 10.D2 and the inability of strain DBA/2 to induce 
lethal runt disease were independent of the incompatible H-2 antigens offered to their 
T  cells, i.e., H-2  b, H-2  f, H-2  q, or H-28. In other words, the two different kinds of GVH 
responsiveness observed with these two donor strains were not antigen specific. 
Because strains DBA/2  and B10.D2  are H-2 identical, the locus or loci coding for 
their different capacities to induce lethal runt disease must be located outside of the 1484  GENETICS OF T  CELL SUPPRESSION IN GRAFI'-VS.-HOST DISEASE 
H-2 complex. This conclusion  is  consistent  with  our observation  that  all  five H-2- 
congenic resistant B 10 donor strains we used were able to induce lethal runt disease. 
A  recessive mode of inheritance  of strain capacity of B10.D2  mice to induce  lethal 
runt disease in (C57BL/10 ×  DBA/2)F1 recipients was indicated by the finding that 
(B10.D2  ×  DBA/2)F1  donors  failed  to  induce  lethal  runt  disease  in  identical  F1 
recipients.  Moreover, we  found  that  a  single  locus  is responsible  for the  difference 
between nonkilling strains DBA/2  and  (B10.D2  ×  DBA/2)F1 on the one hand  and 
the killing strain B 10.D2 on the other (Table II). In conclusion, a recessively inherited 
non-H-2  locus  (or  a  cluster  of closely  linked  loci),  the  products  of which  are  not 
specific for certain  H-2  incompatibilities,  accounts  for the  capability of B10.D2  T 
cells to induce lethal runt disease, by which capacity these T  cells differ from those of 
strain DBA/2. 
As  death  may  result  from  other  causes  than  GVHD,  we  compared  the  effects 
induced  by different  donor strains  by quantitative  parameters as well,  such  as the 
induction  of aplastic anemia as a  result of GVHD  (1).  It is known that, during the 
first  weeks  after  the  induction  of runt  disease,  there  is  a  marked  suppression  of 
erythropoiesis in the bone marrow, which may be partially compensated by a shift of 
erythropoiesis from the marrow to the spleen  (21).  In the present investigation, this 
pattern of anemia and disturbed  hemopoiesis during acute GVHD was found after 
administration of donor spleen cells from both C57BL/10 and B 10.D2, but not those 
from DBA/2  (Table III). Thus, by these parameters, too, T  cells of strain DBA/2, in 
contrast with those of the B 10 strains, proved to be incapable of inducing severe runt 
disease. Furthermore, we found that T  cells obtained from both B 10.D2 and C57BL/ 
10  were  capable  of inducing  the  severe  thymic  hyoplasia  of runt  disease  (1,  22), 
whereas T  cells obtained from strain DBA/2 failed to do so (Table IV). 
The inability of strain DBA/2 to induce lethal runt disease cannot be ascribed to 
a lack ofT lymphocytes in the lymph nodes or spleen, because these organs contained 
closely similar percentages of Thy-l-positive cells in the three different donor strains 
DBA/2,  B10.D2, and C57BL/10  (results not shown).  Nor can the inability of strain 
DBA/2  mice to  induce  runt  disease  be ascribed  to  a  general  inability  to  induce  a 
GVHR. This important conclusion is based on the finding that DBA/2 T  cells were 
an excellent  source of GVH-reactive donor cells when  it  came to  the  induction  of 
autoantibody  formation  (11)  and  increased  IgG production  in  F1  mice  (Table V). 
Interestingly, and  in contrast with the injection  of DBA/2  spleen cells,  injection of 
high doses of spleen cells obtained from the strains on a  B10 background induced a 
suppression  of the splenic  IgG production  of the  recipient  (Table V).  In  all GVH 
assays used, an H-2 incompatibility in the nonirradiated  recipients was required  for 
induction of maximal abnormalities (Tables I, III, and IV). 
Pathogenesis of Lethal Runt Disease.  Because lethal runt  disease  kills the host, and 
because donor T  cells are required  for its induction,  it has been assumed that  runt 
disease is caused by donor T R cells (16,  23).  Support for this assumption came from 
the observation that,  in  general,  the  capacities of different  donor strains  to  induce 
runt disease correlated with their capacity in vitro to generate anti-recipient T K cells 
(24). 
However, direct proof for the involvement of donor T K cells in the pathogenesis of 
lethal runt  disease is missing. Although  donor T K cells with anti-F1  reactivity could 
readily be rescued from the lymphoid tissue of irradiated  F1  recipient  mice  (Fig.  1; VAN ELVEN, ROLINK, VAN DER VEEN, AND GLEICHMANN  1485 
and  [25-27]),  up to now there are no reports that  such T  cells were detectable in 
nonirradiated  F1  hybrid  recipients  undergoing  the  GVHR.  We  found  that  strain 
DBA/2, although it was completely unable to induce runt disease, nevertheless was 
capable of generating T K cells specific for the incompatible H-2 antigens of the F1 
recipients (Figs.  1 and  2;  and Table VII). Therefore, the genetic inability of strain 
DBA/2  to induce lethal runt disease cannot be ascribed to an intrinsic inability of 
this strain to generate anti-Fx T K cells. However, because activated anti-Fa T K cells of 
strain  DBA/2  were studied  only after short-term exposure to F1 antigens  either in 
vitro or in irradiated mice, we cannot exclude the possibility that, in the nonirradiated 
F1 mice used for induction of lethal runt disease, the long-term activation of T K cells 
from strain DBA/2 might have been impaired. If that were so, inhibition of T K cells 
exclusively from strain DBA/2 would account for the inability of this strain to induce 
lethal runt disease. 
Alternatively, a quality in which T  cells from strain DBA/2 unmistakably differed 
from those of the B10 strains was their inability to induce the severe suppression of 
hemopoiesis in the bone marrow, lymphocyte proliferation in the thymus, and IgG 
production  in  the  spleen.  Taken  together,  these  findings  raise  the  possibility  that 
lethal runt disease is caused not, or not only, by donor T ~ cells, but by those donor T 
cells that  generate or mediate suppression of the physiological cell proliferation in 
lymphohemopoietic tissues  (28-31).  The following four observations are consistent 
with this possibility: 
First, in contrast with donor T K cells with anti-F1 specificity, suppressor T  cells of 
the donor strain, which account for the general suppression of immune responsiveness 
during the early GVHR, were readily demonstrable in nonirradiated GVH F1 mice 
(3 l, 33). 
Second, Shand (31)  has provided suggestive evidence that, after the initial specific 
triggering of parental-strain T  cells by the incompatible H-2 antigens of the recipient, 
soluble factors were released that nonspecifically suppressed the formation of plaque- 
forming cells by innocent bystander cells. His finding extended the previous obser- 
vation  that  the  immunosuppression  of GVH  F1  animals  is  nonspecific, because it 
affected not only lymphocytes of the H-2-incompatible Fx host, but  primed spleen 
cells of the parental donor strain as well (32). 
Third, a nonspecific component is also involved in the suppression of hemopoiesis 
caused by the GVHR, because here, too, the suppression affected not only erythro- 
poietic cells of the F1 hybrid recipients but also those of the parental donor strain used 
for induction of the GVHR (34). In this type of experiment, killing of donor strain B 
cells and hemopoietic cells, by T K cells of syngeneic donors can be excluded, because 
donor T  cells are tolerant of syngeneic cells. 
Fourth, a notable feature of runt disease is that it preferentially affects such rapidly 
dividing  tissues  as  the  lympho-hemopoietic tissue  and  the  epithelial  tissue  of the 
gastrointestinal tract and the epidermis, where it induces hypoplasia (1, 2). If donor 
T K cells  were  the  main  effector cells  causing  runt  disease,  then  it  is  difficult  to 
understand  why just  these  highly  proliferating  tissues,  which  have  a  tremendous 
capacity for repair, should suffer most. By contrast, if a nonspecific suppression of cell 
proliferation were involved in the pathogenesis of runt disease, its manifestation would 
be expected precisely in those tissues in which intactness depends on a  high rate of 
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Summary 
When comparing, in a  murine model, the kind of graft-versus-host (GVH) disease 
(GVHD)  induced  by the  donor strain  DBA/2  on  the  one  hand  and  several  H-2- 
congenic resistant B 10 donor strains on the other, we found that strain DBA/2 was a 
universal  nonkilling  GVH  donor  for  H-2-incompatible  nonirradiated  F1  hybrid 
recipients.  In  this  respect,  DBA/2 T  cells  differed  from those of the  H-2-identical 
donor strain B 10.D2 as well as those of other B 10 donor strains. The inability of strain 
DBA/2 to kill  by GVH reaction was not limited to certain H-2 incompatibilities in 
the  F1  recipients,  but  was  nonspecific.  The  inability  to  kill  is  determined  by  a 
dominant locus not linked to H-2. 
DBA/2 T  cells were also incapable of inducing the severe suppression of hematocrit 
values, bone marrow erythropoiesis, thymie cell proliferation, and splenic IgG pro- 
duction in the F~ recipients that was observed after the injection of T  cells from the 
B 10 strains. However, DBA/2 T  cells, in contrast with those of the B 10 donor strains, 
were vigorous stimulators of IgG production in H-2-incompatible F1 hybrid recipients. 
Surprisingly, strain  DBA/2 as well as the B10 donor strains had a  good capacity to 
generate anti-F1 T K cells. 
Taken together, these findings raise the possibility that lethal GVHD disease is not 
caused, or not caused exclusively, by donor killer T  cells,  but by those donor T  cells 
that  directly or indirectly induce a  suppression  of cell  proliferation  in  certain  vital 
organs of the recipient. 
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